Page 87 - Memora anual Fundación CIEN 2015
P. 87
5. INTERNATIONAL RELATIONS
Total Funding: 2,2 M€ (approx.) operation between neurologists, neuropathologists
and neuroscientists.
Start Date: May, 2012
Our goals are:
Duration: 3 years
• To harmonize the protocols involved in patient
Coordinator: Inga Zerr, University Medical documentation, biomaterial sampling/ storage,
biomarker testing/assay analysis and data
Center Göttingen, Germany sharing.
CIEN Foundation participation: Miguel Calero • To standardise a more precise diagnosis in
patients with rapidly progressive dementia by
Project partners: analysis of the biochemical markers in the
cerebrospinal fluid and blood.
• Inga Zerr, University Medical Center
Göttingen, Germany • To improve CSF based diagnosis in dementia by
application of new methodologies.
• Carsten Korth, Heinrich Heine University
Medical School, Düsseldorf, Germany In DEMTEST we work on standardisation of tests that
are currently available and harmonise their use bet-
• Hans Kretzschmar, Ludwig-Maximilians- ween centers worldwide. We define standards for
University, Munich, Germany biochemically based diagnosis in most relevant
rapid progressive dementia such as CJD and rapidly
• Jean-Louis Laplanche, Hopital Lariboisiere AP- progressive Alzheimer’s disease. We will improve in-
HP, France novative methods for amplification assays for mis-fol-
ded proteins and introduce their use into clinical
• Olivier Andreoletti, UMR-INRA-EVNT, France routine. As an add-on value, we will define criteria
• Theodoros Sklaviadis, Aristotle University of for early differential diagnosis between rapidly pro-
gressive neurodegenerative or potentially reversible
Thessaloniki, Greece dementia.
• Stefano Ruggieri & Maurizio Pocchiari & Anna
The DEMTEST collaboration allowed us to perform a
Ladogana, University “Sapienza”, Rome, Italy genome wide association study (GWAS) in prion di-
• Pawel Liberski, Medical University of Lodz, seases. Because of that, we published in 2012 an as-
sociation between MTMR7 gene and susceptibility to
Poland new variant Creutzfeldt-Jakob disease (CJD); this
• Catarina Resende Oliveira, University of study was followed by an attempt of sequencing our
top candidate genes where we found a risk variant
Coimbra, Portugal in PLCXD3 gene. In 2014, we finalized the second
• Eva Mitrová, Slovak Medical University part of our analysis; we performed a GWAS and re-
plicated the results with samples from sporadic CJD
Bratislava, Slovakia patients from all partner countries. We have suc-
• Gorazd Bernard Stokin, University Psychiatric
Hospital, Ljubljana, Slovenia
• Miguel Calero, Carlos III National Health
Institute, Spain
• Pascual Sanchez-Juan, IFIMAV and CIBERNED,
University Hospital, Spain
• Anna-Lena Hammarin, Swedish Institute of
Communicable Disease Control, Sweden
• Adriano Aguzzi & Herbert Budka, University
Hospital Zürich, Switzerland
• John Collinge, University College London,
United Kingdom
• Robert G. Will, Western General Hospital,
United Kingdom
DEMTEST has established a large European and glo-
bal collaboration between national surveillance
units and dementia research centres, facilitating co-
CIEN Foundation Annual Report 2015 / 89
